Affirma Biotech

affirmabio.com ↗ ·Barcelona ·Seed

Barcelona-based preclinical biotech developing orally available, host-directed immunotherapeutic drugs to treat severe respiratory infections such as hospitalized influenza and community-acquired pneumonia, as well as chronic hepatitis B. Founded in 2020 and based at the Sant Pau Recinte Modernista, it has raised seed funding (€600K in 2022, €1.75M in 2024) plus non-dilutive CDTI/NEOTEC and EU NextGenerationEU grants.

Founded

2020

Founders

Total funds raised

€2.4M

SectorsBiotech, Immunotherapy, Anti-infectives, Drug Discovery Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Joan Feixas

Co-founder

Maribel Berges

CEO & Co-founder

Global models 5

Vir Biotechnology

United States · www.vir.bio ↗

Immunology-based biotech developing therapies (including host-directed approaches) against major infectious diseases like influenza and hepatitis B/D, the closest large-scale model match.

$566MComparable

Aligos Therapeutics

United States · www.aligos.com ↗

Clinical-stage biotech developing oral antiviral therapeutics targeting chronic hepatitis B, directly mirroring Affirma's HBV program.

$225MComparable

Assembly Biosciences

United States · www.assemblybio.com ↗

Biotech focused on curative oral therapies for chronic hepatitis B and other viral/microbiome-driven diseases.

$175MComparable

Arbutus Biopharma

United States · www.arbutusbio.com ↗

Develops therapeutics aimed at achieving a functional cure for chronic hepatitis B, same target indication as Affirma.

$142MComparable

Cidara Therapeutics

United States · www.cidara.com ↗

Develops immunotherapy-based anti-infective drug conjugates (Cloudbreak platform) for respiratory and other infections, paralleling Affirma's immunomodulatory anti-infective approach.

$150MComparable